🔗 Share this article The Global Health Body Sounds Alert Over Acute Shortage of Obesity Jabs Under a tenth of people who could benefit from weight-loss injections including Wegovy are able to get them, warns the WHO as it issues its initial recommendations on the medications. With more than one billion individuals worldwide currently classified as obese, it is calling for broader and more equitable availability to GLP-1 medication. Based on projections, more than two billion will be obese by 2030 without intervention. "The latest guidance recognises that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to broad availability to the treatments that can help people shift substantial weight, says the agency. Weight-Loss Drug Shortage Despite the present most optimistic scenario, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of those who need them, according to the health organization. The advice calls on nations and manufacturers to widen access, through strategies like voluntary licensing. A patent on the active ingredient – the main component of the drug Wegovy – is set to lapse in multiple countries in 2026. The Way Weight-Loss Drugs Function The injections imitate a body's own hormone to reduce digestion speed, suppress the appetite and boost the sense of being full so individuals reduce food intake. Individuals typically begin shedding pounds within a few weeks of beginning the regular doses. Research suggests patients may put most of the weight back on a year later of halting the medication, because their usual appetite return. To be above a healthy weight elevates your chance for developing medical conditions, like diabetes, cardiovascular issues, stroke, and certain cancers. Obesity impacts individuals in all nations and was associated with millions of fatalities worldwide in 2024, according to the WHO.
Under a tenth of people who could benefit from weight-loss injections including Wegovy are able to get them, warns the WHO as it issues its initial recommendations on the medications. With more than one billion individuals worldwide currently classified as obese, it is calling for broader and more equitable availability to GLP-1 medication. Based on projections, more than two billion will be obese by 2030 without intervention. "The latest guidance recognises that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to broad availability to the treatments that can help people shift substantial weight, says the agency. Weight-Loss Drug Shortage Despite the present most optimistic scenario, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of those who need them, according to the health organization. The advice calls on nations and manufacturers to widen access, through strategies like voluntary licensing. A patent on the active ingredient – the main component of the drug Wegovy – is set to lapse in multiple countries in 2026. The Way Weight-Loss Drugs Function The injections imitate a body's own hormone to reduce digestion speed, suppress the appetite and boost the sense of being full so individuals reduce food intake. Individuals typically begin shedding pounds within a few weeks of beginning the regular doses. Research suggests patients may put most of the weight back on a year later of halting the medication, because their usual appetite return. To be above a healthy weight elevates your chance for developing medical conditions, like diabetes, cardiovascular issues, stroke, and certain cancers. Obesity impacts individuals in all nations and was associated with millions of fatalities worldwide in 2024, according to the WHO.